| ID Source | ID |
|---|---|
| PubMed CID | 13041095 |
| CHEMBL ID | 1089222 |
| SCHEMBL ID | 8975264 |
| MeSH ID | M0110114 |
| Synonym |
|---|
| bendazac l-lysine |
| l-lysine, mono(((1-(phenylmethyl)-1h-indazol-3-yl)oxy)acetate) |
| af 1934 |
| bendalina |
| bendazac lysine |
| bendazaco lisina [spanish] |
| lysine salt of ((1-(phenylmethyl)-1h-indazol-3-yl)oxy)acetic acid |
| bendaline |
| l-lysine, ((1-(phenylmethyl)-1h-indazol-3-yl)oxy)acetate |
| 81919-14-4 |
| CHEMBL1089222 |
| bendazac lysine salt |
| af-1934 |
| l-lysine-(1-benzyl-1h-indazol-3-yloxy)acetic acid |
| cl7t957egc , |
| ec 617-268-5 |
| bendazaco lisina |
| l-lysine, 2-((1-(phenylmethyl)-1h-indazol-3-yl)oxy)acetate (1:1) |
| unii-cl7t957egc |
| S5867 |
| bendazacl-lysine |
| SCHEMBL8975264 |
| bendazac lysine [mart.] |
| bendazac lysinate [who-dd] |
| bendazac lysine salt [mi] |
| bendazac lysinate |
| CS-8031 |
| HY-B2165 |
| mfcd07776898 |
| bendazac l-lysine, aldrichcpr |
| (2s)-2,6-diaminohexanoic acid; 2-[(1-benzyl-1h-indazol-3-yl)oxy]acetic acid |
| bendazac lysine,(s) |
| (s)-2,6-diaminohexanoic acid compound with 2-(1-benzyl-1h-indazol-3-yloxy)acetic acid (1:1) |
| AS-14245 |
| D70706 |
| Q27275520 |
| AKOS016844132 |
| A864481 |
| 2-(1-benzylindazol-3-yl)oxyacetic acid;(2s)-2,6-diaminohexanoic acid |
| 2-(1-benzylindazol-3-yl)oxyacetate;(2s)-2,6-bis(azaniumyl)hexanoate |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The rate of absorption of bendazac, as assessed by tmax and Cmax, is similar in patients and in healthy subjects." | ( The pharmacokinetics of bendazac-lysine and 5-hydroxybendazac, its main metabolite, in patients with hepatic cirrhosis. Campistron, G; Ego, D; Escourrou, J; Houin, G; Ribet, A; Rovei, V; Thiola, A, 1988) | 0.27 |
| " The pharmacokinetic parameters were compared to those obtained in 10 healthy adult volunteers." | ( Pharmacokinetics of bendazac-lysine and 5-hydroxybendazac in patients with renal insufficiency. Campistron, G; Conte, JJ; Dueymes, JM; Ego, D; Houin, G; Rovei, V, 1987) | 0.27 |
| "The plasma concentration-time curve was fitted to 2-compartment open model, and the major pharmacokinetic parameters of domestic and imported BL tablets were shown respectively as following: Cmax 66 +/- 16 and 65 +/- 8 mg." | ( Pharmacokinetics of bendazac lysine in 10 Chinese young men. Chen, XX; Pu, J; Qiu, JJ; Shen, JP; Yan, HY; Zhang, YD; Zhu, YQ, 1997) | 0.3 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The rate of absorption of bendazac, as assessed by tmax and Cmax, is similar in patients and in healthy subjects." | ( The pharmacokinetics of bendazac-lysine and 5-hydroxybendazac, its main metabolite, in patients with hepatic cirrhosis. Campistron, G; Ego, D; Escourrou, J; Houin, G; Ribet, A; Rovei, V; Thiola, A, 1988) | 0.27 |
| " The bioavailability of the domestic vs that of the imported tablet was 99 +/- 12%." | ( Pharmacokinetics of bendazac lysine in 10 Chinese young men. Chen, XX; Pu, J; Qiu, JJ; Shen, JP; Yan, HY; Zhang, YD; Zhu, YQ, 1997) | 0.3 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Results from a very small number of preliminary studies using objective photographic and densitometric methods have suggested that oral bendazac lysine, usually at a dosage of 500 mg 3 times daily, can stabilise the progression of lens opacification in patients with cataract." | ( Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts. Balfour, JA; Clissold, SP, 1990) | 0.28 |
| " Overall it can be assumed that the pharmacological effect of the drug will not be enhanced in renal failure and that the dosage regimen of bendazac-lysine in such patients need not be modified." | ( Pharmacokinetics of bendazac-lysine and 5-hydroxybendazac in patients with renal insufficiency. Campistron, G; Conte, JJ; Dueymes, JM; Ego, D; Houin, G; Rovei, V, 1987) | 0.27 |
| " In vivo the protective effect has been observed after treatments ranging in duration from 3 to 14 days depending on the dosage used; the minimal effective dose produced a serum level of 35 micrograms/ml of bendazac." | ( Basic data supporting the use of the l-lysine salt of bendazac in cataract. Barillari, G; Catanese, B; Iorio, E; Silvestrini, B; Valeri, P, 1983) | 0.27 |
| "6% respectively of the dosage in 24 h after a single oral dose." | ( Pharmacokinetics of bendazac lysine in 10 Chinese young men. Chen, XX; Pu, J; Qiu, JJ; Shen, JP; Yan, HY; Zhang, YD; Zhu, YQ, 1997) | 0.3 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID473552 | Induction of water-solvent protein level in rabbit lens homogenates at 5 mM (Rvb= 7.40 +/-0.73 mg/mL) | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473531 | Anticataract activity against FeCl3/H2O2-induced cataract in rabbit lens assessed as absence of opacificaion at 0.5 mM treated 1 hr before FeCl3/H2O2 challenge measured after 24 hrs | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473558 | Reduction of malondialdehyde level in rabbit lens homogenates at 5 mM (Rvb= 0.46 +/-0.27 nmol/mg) | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473532 | Anticataract activity against FeCl3/H2O2-induced cataract in rabbit lens assessed as slight degree of opacificaion at 0.5 mM treated 1 hr before FeCl3/H2O2 challenge measured after 24 hrs | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473533 | Anticataract activity against FeCl3/H2O2-induced cataract in rabbit lens assessed as middle degree of opacificaion at 0.5 mM treated 1 hr before FeCl3/H2O2 challenge measured after 24 hrs | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID1386482 | Inhibition of alpha-crystallin B R120G mutant (unknown origin)-induced intracellular protein aggregation expressed in human HeLa cells at 4 uM incubated for 6 to 8 hrs by fluorescence microscopy relative to untreated control | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | Synthesis, Evaluation, and Structure-Activity Relationship Study of Lanosterol Derivatives To Reverse Mutant-Crystallin-Induced Protein Aggregation. |
| AID473539 | Anticataract activity against FeCl3/H2O2-induced cataract in rabbit lens assessed as absence of opacificaion at 10 mM treated 1 hr before FeCl3/H2O2 challenge measured after 24 hrs | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473537 | Anticataract activity against FeCl3/H2O2-induced cataract in rat lens assessed as middle degree of opacificaion at 0.5 mM treated 1 hr before FeCl3/H2O2 challenge measured after 24 hrs | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473540 | Anticataract activity against FeCl3/H2O2-induced cataract in rabbit lens assessed as slight degree of opacificaion at 10 mM treated 1 hr before FeCl3/H2O2 challenge measured after 24 hrs | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473536 | Anticataract activity against FeCl3/H2O2-induced cataract in rat lens assessed as slight degree of opacificaion at 0.5 mM treated 1 hr before FeCl3/H2O2 challenge measured after 24 hrs | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473555 | Induction of total-antioxidant capacity level in rabbit lens homogenates at 5 mM (Rvb= 0.04 u/mg) | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473535 | Anticataract activity against FeCl3/H2O2-induced cataract in rat lens assessed as absence of opacificaion at 0.5 mM treated 1 hr before FeCl3/H2O2 challenge measured after 24 hrs | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473530 | Aqueous solubility of the compound | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473541 | Anticataract activity against FeCl3/H2O2-induced cataract in rabbit lens assessed as middle degree of opacificaion at 10 mM treated 1 hr before FeCl3/H2O2 challenge measured after 24 hrs | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473542 | Anticataract activity against FeCl3/H2O2-induced cataract in rabbit lens assessed as extensive mature nuclear opacity at 10 mM treated 1 hr before FeCl3/H2O2 challenge measured after 24 hrs | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473538 | Anticataract activity against FeCl3/H2O2-induced cataract in rat lens assessed as extensive mature nuclear opacity at 0.5 mM treated 1 hr before FeCl3/H2O2 challenge measured after 24 hrs | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| AID473534 | Anticataract activity against FeCl3/H2O2-induced cataract in rabbit lens assessed as extensive mature nuclear opacity at 0.5 mM treated 1 hr before FeCl3/H2O2 challenge measured after 24 hrs | 2010 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7 | Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 17 (42.50) | 18.7374 |
| 1990's | 17 (42.50) | 18.2507 |
| 2000's | 3 (7.50) | 29.6817 |
| 2010's | 3 (7.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 6 (13.95%) | 5.53% |
| Reviews | 1 (2.33%) | 6.00% |
| Case Studies | 1 (2.33%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 35 (81.40%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||